Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of DNLI is 33 and suggests 57% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell